louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03264118: Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions
Official title: Effects of Antimicrobial Photodynamic Therapy Associated to Biomaterials on Regeneration of Class II Furcation Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontitis, Chronic
Periodontal Diseases
Periodontal Bone Loss
Keywords: Periodontal Guided Tissue Regeneration
Photochemotherapy
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Geistlich Pharma AG
First posted: 2017-08-28
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Split-mouth design. One side of mouth is test and the other is control side.
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the additional effect of antimicrobial photodynamic therapy regeneration treatment of mandibular furcation lesions when associated to bovine bone and porcine collagen membrane.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of class II furcation lesion in mandibular 1st and 2nd molars
* Mandibular 1st and 2nd molars without caries, erosion or abrasion

Exclusion Criteria:

* Smoking habit
* Pregnancy
* Use of antibiotics in the last six months
* Periodontal treatment in the last six months
* Endodontic lesion
* Systemic diseases that impair wound healing

Primary outcomes:
measure: Horizontal probing depth
timeFrame: one year
measure: Tomographic Bone filling
timeFrame: One year
Secondary outcomes:
measure: Probing depth
timeFrame: one year
measure: Clinical Attachment Level
timeFrame: one year
measure: Bleeding on probing
timeFrame: One year
Other outcomes:
Locations:
city: Bauru
country: Brazil
facility: Bauru School of Dentistry
state: Sao Paulo
city: Bauru
country: Brazil
facility: Bauru School of Dentistry
Study officials:
References:
citation: Luchesi VH, Pimentel SP, Kolbe MF, Ribeiro FV, Casarin RC, Nociti FH Jr, Sallum EA, Casati MZ. Photodynamic therapy in the treatment of class II furcation: a randomized controlled clinical trial. J Clin Periodontol. 2013 Aug;40(8):781-8. doi: 10.1111/jcpe.12121. Epub 2013 Jun 3.
citation: Avila-Ortiz G, De Buitrago JG, Reddy MS. Periodontal regeneration - furcation defects: a systematic review from the AAP Regeneration Workshop. J Periodontol. 2015 Feb;86(2 Suppl):S108-30. doi: 10.1902/jop.2015.130677.
Clinical trial NCT06950918: Flipped Classroom vs. Flip-Jigsaw in Theoretical Physiotherapy Education
Official title: The Role of Flipped Classroom and Flip-Jigsaw in Theoretical Physiotherapy Education: A Comparison of Knowledge, Motivation and Engagement
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Physiotherapy and Rehabilitation
Educational Technology
Educational Interventions
Students
Undergraduate Health Professional Students
Keywords: Flipped Clasroom
Flip-J
Learning Model
Physiotherapy education
Lead sponsor: Isparta University of Applied Sciences
Sponsor class: OTHER
Collaborators: name: Suleyman Demirel University
First posted: 2025-04-30
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Study Summary:

This quasi-experimental pre-test-post-test study aims to compare the effects of Flipped Classroom (FC) and Flip-Jigsaw instructional models on theoretical knowledge acquisition, academic motivation, and class engagement among 86 third-year physiotherapy undergraduates enrolled in a theory-based public health course.

Primary Questions:

How does the hybrid Flip-Jigsaw model impact learning and motivation outcomes compared to FC alone?

Do FC and Flip-Jigsaw differ in enhancing theoretical knowledge, motivation, and participation?

Comparison: Researchers will compare the FC group (pre-class videos + in-class discussions) with the Flip-Jigsaw group (video-based pre-learning + structured peer teaching) to evaluate differences in outcomes.

Participant Tasks:

Attend lectures and complete pre-/post-knowledge tests.

Engage in practical sessions (FC: group discussions; Flip-Jigsaw: peer-led jigsaw activities).

Complete motivation surveys and participation assessments.

Significance: Addresses the gap in understanding Flip-Jigsaw's efficacy in physiotherapy education, despite prior reports on FC and Jigsaw's individual benefits.


Eligibility criteria: Inclusion Criteria:

* To be between the ages of 18-25
* Volunteering to participate in the study
* Taking the course for the first time
* Having access to the Internet
* Compulsory course attendance

Exclusion Criteria:

* Being a minor student
* Not being the first undergraduate education
* To have previously attended courses, seminars, webinars, etc. related to public health
* Participation in other pedagogical studies during the same academic term.
* Failure to complete ≥1 assessment (pre-test, post-test, or surveys).

Primary outcomes:
measure: Level of theoretical knowledge
timeFrame: pre-test and immediately after the intervention (7 weeks after study enrollment)
measure: Level of motivation
timeFrame: immediately after the intervention (7 weeks after study enrollment)
measure: Level of student engagement
timeFrame: immediately after the intervention (7 weeks after study enrollment)
Secondary outcomes:
Other outcomes:
Locations:
city: Isparta
country: Turkey
facility: Süleyman Demirel University
Study officials:
References:
Clinical trial NCT04483518: Epidemiological Survey of Hepatitis D Virus Infection in China
Official title: Epidemiological Survey of Hepatitis D Virus Infection in Hepatitis B Population Among Multi-center Hepatitis B Population in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Observe and Describe the Prevalence of Hepatitis D Infection Among HBsAg Positive People
Keywords: HBsAg positive
HBV DNA
Lead sponsor: The First Hospital of Jilin University
Sponsor class: OTHER
Collaborators: name: Nanfang Hospital, Southern Medical University
name: The Fourth Affiliated Hospital of Harbin Medical University
name: Shandong Provincial Hospital
name: Ruijin Hospital
First posted: 2020-07-23
Enrollment: 5000
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Hepatitis B surface antigen or HBV DNA positive

Brief summary: This cross-sectional study will screen out hepatitis D virus-infected patients in HBsAg-positive people. Observe and describe the prevalence of hepatitis D infection among HBsAg positive people. The provinces of China are divided into 5 geographical areas (North, South, East, West and Central) to recruit patients according to the population density of each area. After statistical calculation, the total number of population needed is 3808.

Detailed description: Entry criteria：1. Age 18 years and above. 2. male or female. 3. Diagnosed as chronic HBV infection (HBsAg positive) 4.Ability to sign informed consent.

Exclusion criteria：Patients who disagree to participate in the trial.

After the informed consent was signed, the quantitative data of the previous surface antigen or HBV DNA titer was collected during the return visit. 4 ml of venous blood was collected on the same day or the remaining serum from the surface antigen or hepatitis B quantitative test was collected for the detection of hepatitis D antibody and/or the quantitative detection of hepatitis D RNA.

After statistical analysis, calculate the hepatitis D infection status in China.

Eligibility criteria: Inclusion Criteria:

* Hepatitis B surface antigen or HBV DNA positive

Exclusion Criteria:

* Can't sign informed consent

Primary outcomes:
measure: The prevalence of hepatitis D virus
timeFrame: 2019-2020
Secondary outcomes:
Other outcomes:
Locations:
city: Changchun
country: China
facility: the first hospital of Jilin University
state: Jilin
Study officials:
affiliation: The First Hospital of Jilin University
name: Junqi Niu, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04709718: Surgical Management of Giant Hepatic Hemangioma
Official title: Surgical Management of Giant Hepatic Hemangioma: a 10-year Single Center Experience
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Angioma
Lead sponsor: Université de Sousse
Sponsor class: OTHER
Collaborators: name: Sahloul Hospital of Sousse
First posted: 2021-01-14
Enrollment: 12
Sex: ALL
Minimum age (years): 15
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient with symptomatic geant liver hemangioma

Brief summary: Hepatic hemangiomas are the commonest benign mesenchymal lesions of the liver. Most of these lesions are asymptomatic. Giant hepatic hemangiomas (GHH) (\> 10 cm) are often symptomatic and require surgical intervention. This study aimed to describe the clinical findings, risk factors, diagnostic approach and management of GHH.

Detailed description: Hepatic hemangiomas are the most common benign tumors of the liver with the incidence of 0.4 to 20% . They are most often discovered incidentally on imaging studies. Typical hemangiomas usually do not increase in size over time and therefore are unlikely to cause symptoms. Giant hepatic hemangiomas (GHH) are defined as hemangiomas larger than 5 cm . They are usually responsible for overt clinical symptoms and complications consisting, most often, of upper abdominal pain, hemorrhage, biliary compression, or a consumptive coagulopathy that may require prompt surgical intervention or other treatments . Management of liver hemangiomas ranges from close observation to surgery depending upon the site, size and symptoms .

It is widely accepted that intervention is indicated only for symptomatic hemangiomas. Surgical resection is indicated in patients with abdominal complaints or complications, or when diagnosis remains inconclusive. The ideal surgical treatment for GHH is still controversial. Enucleation is the preferred surgical method based on the existing literature. In this study, we report our 17-year experience of clinical management of GHH.

Eligibility criteria: Inclusion Criteria:

* Radiological diagnosis of geant liver hamangioma.

Exclusion Criteria:

* Radiological diagnosis of liver hemangioma less than 10cm.

Primary outcomes:
measure: number of patient getting good result after surgery
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: university of sousse
name: waad farhat, doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01552018: Saxagliptin and Atherosclerosis
Official title: Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Diabetes Mellitus Type 2
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2012-03-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dipeptidyl peptidase 4 (DPP-4) inhibitors are approved as add on therapy to improve glycaemic control in Type 2 Diabetes Mellitus (T2DM). DPP-4 inactivates the incretin hormone glucagon-like peptide 1 (GLP-1). Inhibiting the inactivation of GLP-1 leads to increased insulin- and reduced glucagon secretion after meals. DPP-4 has been shown to be present in atherosclerotic plaques. DPP-4 is a protease with substrates including cytokines and chemokines associated with atherosclerosis/inflammation.

The purpose of this study is to explore the effects of 3 months intervention with DPP-4 inhibitor saxagliptin on biomarkers related to atherosclerosis in patients with stable coronary artery disease (CAD) and T2DM, on circulating levels and on expression levels in circulating monocytes and adipose tissue.

A reduction in markers associated with atherosclerosis could indicate an antiatherosclerotic effect of DPP-4 inhibitors beyond glycaemic control alone.

Due to reduced sample size (recruitment problems) the main focus has changed and will now be on cellular aspects and gene regulation (initially secondary outcome measure).


Eligibility criteria: Inclusion Criteria:

* Patients \> 18, \< 80 years old, with type 2 diabetes mellitus and angiographically proven coronary artery disease.
* HbA1c \> 6.5% and under treatment with either metformin and/or glimepiride.

Exclusion Criteria:

* Allergy or hypersensitivity to any of the drug's components.
* Heart failure in NYHA class III or IV.
* Severe liver failure, moderate or severe kidney failure
* Malignant disease.
* Active infectious disease.
* Acute coronary syndrome in the last 3 months.
* Pregnancy or breastfeeding.

Primary outcomes:
measure: Inflammatory biomarkers
timeFrame: Changes in biomarkers from baseline to 3 months
Secondary outcomes:
measure: Gene expression of DPP-4 in adipose tissue and leukocytes
timeFrame: Change in expression level of DPP-4 from baseline to 3 months
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal
Study officials:
affiliation: Center for Clinical Heart Research, Dept. of Cardiology, Oslo University Hospital Ullevaal, Norway
name: Ida U Njerve, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03426618: A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B
Official title: A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis B
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2018-02-08
Enrollment: 1
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be enrolled with chronic hepatitis B virus (CHB)between the ages of 2 and less than 16 years and who will begin treatment with Baraclude.

Brief summary: This is a local, prospective observational study (regulatory post marketing surveillance) to access the safety and effectiveness of Baraclude in Korean pediatric patients with chronic HBV infection who are between the ages of 2 and less than 16 years.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* 2 to \< 16 years of age
* Patients with chronic hepatitis B infection, eligible for treatment with Baraclude as indicated in the locally approved prescribing information

Exclusion Criteria:

* Off-label use of the approved label in Baraclude pediatric indication
* Patients with a contraindication for the use of Baraclude as described in the locally approved prescribing information

Other protocol defined inclusion/exclusion criteria could apply

Primary outcomes:
measure: Number of Adverse Events (AEs)
timeFrame: Up to 52 weeks
Secondary outcomes:
measure: Participants who achieved a virologic response
timeFrame: Up to 48 weeks
measure: Mean log reduction in hepititis B virus DNA
timeFrame: Baseline to Weeks 12, 24, and 48
measure: Liver stiffness
timeFrame: Baseline and Week 48 of treatment
measure: Number of participants with resistance to Baraclude
timeFrame: Up to 52 weeks
measure: Number of participants with virologic relapse in participants
timeFrame: Up to 48 weeks
measure: Number of participants with virologic Relapse in participants
timeFrame: Up to 48 weeks
measure: Number of participants who were HBeAg seroconverted at Week 48
timeFrame: Week 48
measure: Number of participants who had HBeAg loss at week 48
timeFrame: Week 48
measure: Number of participants who were HBsAg seroconverted at Week 48
timeFrame: Week 48
measure: Number of participants who had HBsAg loss at week 48
timeFrame: Week 48
measure: Number of participants with normalization of serum ALT at week 12
timeFrame: Baseline to week 12
measure: Number of participants with normalization of serum ALT at week 24
timeFrame: Baseline to week 24
measure: Number of participants with normalization of serum ALT at week 48
timeFrame: Baseline to week 48
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT01880918: A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
Official title: Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diverticulum, Colon
Colorectal Neoplasms
Crohn Disease
Colitis, Ulcerative
Colostomy
Ileostomy - Stoma
Rectal Prolapse
Intestinal Polyposis
Lymphoma
Endometriosis
Intestinal Volvulus
Keywords: Compression Anastomosis
Lead sponsor: novoGI
Sponsor class: INDUSTRY
First posted: 2013-06-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients who underwent a laparoscopic or open Low Anterior resection with the creation of an anastomosis using the ColonRing in routine clinical practice.

Brief summary: The proposed study is a post marketing, observational, retrospective data collection intended to gather and record data on patients treated with the ColonRing device in routine clinical practice at 4-6 centers. The data will assist in future evaluating the performance of the ColonRing device in regards to the creation of a colorectal anastomosis in Low Anterior Resection procedures.

Hypothesis: The performance of the ColonRing, determined by the rate of complications, will be within the acceptable range reported in the literature for alternative treatment modalities.


Eligibility criteria: Inclusion Criteria:

1. Patient was \> 18 years old at time of procedure
2. Patient underwent a technically successful open or laparoscopic colorectal, Low Anterior Resection procedure with the creation of an anastomosis using the ColonRing™
3. Patient treated in routine clinical practice
4. Patient underwent his/her first follow-up visit within two months post-surgery

Exclusion Criteria:

No exclusion criteria have been defined for this data collection.

Primary outcomes:
measure: The rate of anastomotic leakage.
timeFrame: 6 weeks after the procedure
Secondary outcomes:
measure: Rate of other device related complications and measures during hospitalization and post procedure.
timeFrame: 6 weeks after the procedure.
Other outcomes:
Locations:
city: Atlamonte Springs
country: United States
facility: Florida Hospital, Center for Colon & Rectal Surgery
state: Florida
city: Port Charlotte
country: United States
facility: 18308 Murdock Circle, Suite 108
state: Florida
city: Springfield
country: United States
facility: CoxHealth Hospital, Colorectal Department
state: Missouri
Study officials:
References:
Clinical trial NCT05752318: Analysis of the Persistence, Reservoir and HIV Latency
Official title: APRIL Study: Analysis of the Persistence, Reservoir and HIV Latency
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: HIV Infected Individuals
Informed Consent
Keywords: HIV
Reservoir
Latency
Persistence
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-03-02
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HIV-infected adults

Brief summary: The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.


Eligibility criteria: Inclusion Criteria:

* HIV-infection
* Adults (\>18 years)
* Social insurance
* Informed consent

Exclusion Criteria:

* HIV-uninfected
* \<18 years
* Lack of social insurance
* Lack or withdraw of consent

Primary outcomes:
measure: HIV-Flow
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07012018: Pancreas Screening in High Risk Individuals
Official title: Pancreas Screening in High Risk Individuals: A Prospective Cohort
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pancreas Cancer Screening
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: High risk individuals referred for pancreas screening

Brief summary: Pancreas cancer is the 11th most common cancer in Canada but the 4th most common cause of cancer death because by the time pancreas cancer is detected, it is almost always too advanced for surgery. There are known factors that put individuals at higher risk for pancreas cancer. These include: certain genetic mutations, a family history of pancreas cancer, pancreas cysts and a new diagnosis of diabetes mellitus. Individuals with these risk factors are recommended to undergo pancreas screening with blood tests and yearly imaging tests of the pancreas. Our study will enroll patients with these risk factors and ensure they are managed as per guidelines. Prospectively collected data will include: patient clinicodemographic details, lifestyle factors, screening test results, clinical outcomes and patient reported outcome measures.


Eligibility criteria: Inclusion Criteria:

* Family history of pancreatic cancer, pathogenic variant increasing risk of pancreatic cancer, IPMN, new onset diabetes.

Exclusion Criteria:

* Unable to give informed consnet

Primary outcomes:
measure: Incidence of pancreatic cancer
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: